Drug Trial Radar · NCT07053384
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
107
Actual
Start
Jul 10, 2025
Primary completion
Jan 22, 2027
Study completion Sep 6, 2028
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2). The study is designed to include the following phases: Randomized Intervention Phase (Step 1), Analytical Treatment Interruption (ATI) Phase (Step 2), and Follow-up Phase (Step 3).
Conditions
- HIV Infections
Interventions
VH3810109Biological
VH3810109 will be administered.
Fostemsavir (FTR)Drug
Fostemsavir will be administered.
SOC INSTI-based ARTDrug
A SOC INSTI-based ART regimen will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Randomized Intervention Phase (Step 1): Change from baseline in cell-associated HIV-1 RNA transcripts per million cluster of differentiation 4 (CD4+) T cellsTime frame: From Baseline (Day 1) to Month 12
Locations
41 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Ft. Pierce, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
New York, New York
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Ghent, Oost-Vlaanderen, Belgium
GSK Investigational Site
Hvidovre, Capital Region, Denmark
GSK Investigational Site
Aarhus N, Central Jutland, Denmark
GSK Investigational Site
Rotterdam, Netherlands
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Córdoba, Spain
GSK Investigational Site
La Laguna Santa Cruz, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Palma de Mallorca, Spain
GSK Investigational Site
Palma de Mallorca, Spain
GSK Investigational Site
Seville, Spain
GSK Investigational Site
Valencia, Spain
GSK Investigational Site
Valencia, Spain
GSK Investigational Site
Pozuelo de Alarcón, Madrid, Spain
GSK Investigational Site
London, United Kingdom
GSK Investigational Site
London, United Kingdom
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.